Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

These two studies, one in type 1 diabetes patients and the other in type 2 patients, will each enroll approximately 110 patients. The primary endpoint will be a comparison of glycemic control, as assessed by the change in A1C from baseline.
  • An equity financing raised net proceeds of $60 million through a public offering of 8.3 million newly issued shares of common stock. The offering closed on September 14, 2010.
  • Halozyme completed its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. We have been in communication with the U.S. Food and Drug Administration (FDA), and have provided them materials relating to the root cause and remediation plans.
  • Recently, Halozyme redirected its resources to concentrate on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and to support its strategic alliances with Roche and Baxter. Halozyme will continue full development of its Phase 2 Ultrafast Insulin, Phase 1 PEGPH20, and preclinical HTI-501 programs, and has decreased research relating to the discovery and preclinical assessment of new compounds. This strategy resulted in reduction in the workforce of approximately 25 percent.
  • Baxter presented two posters with interim data from its Phase 3 clinical trial of HyQ at the European Society for Immunodeficiencies meeting in Istanbul, Turkey on October 6-9, 2010. HyQ is an immunoglobulin therapy facilitated subcutaneously by Halozyme's recombinant human hyaluronidase. Interim analyses showed that 28 out of 29 HyQ-treated study participants with primary immune deficiency were able to infuse immunoglobulin under the skin, using a single injection site, at infusion volumes, intervals and rates equivalent to their previous intravenous (IV) administration of immunoglobulin. 
  • Roche presented a poster of its Phase 1 clinical trial for Her
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
    (Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
    (Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
    (Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
    Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
    ... Fla., Oct. 7 GeneWize Life Sciences ... Bulletin Board: GNLK) announced before a full house of ... targeting the teen market, adding to their current flagship ... The new nutrition and skin-clearing products, aimed ...
    ... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Executive Officer of BioMarin, will host a ... 28, at 5:00 p.m. ET to discuss ... Dial-in Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: ...
    ... JOSEPH, Mich., Oct. 7 GeneGo, Inc., a leading ... and chemistry, announced today that they have integrated GenomeQuest,s ... MetaDrug. Using GenomeQuest,s interactive analysis, scientists who ... of interest (hundreds of millions of reads, to thousands ...
    Cached Biology Technology:GeneWize Announces New Skin Clearing Product and Teen Nutrition at Annual Convention 2BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET 2GeneGo Announces Integration With GenomeQuest for Pathway Analysis of Next Generation Sequencing Data 2
    (Date:7/9/2014)... to species, selection for traits that are attractive to ... enhances opportunities to mate, the tail of male peacocks ... of California, Riverside have now found that sexual selection ... are linked. Describing the life histories of more than ... researchers found that species with placentas tend to have ...
    (Date:7/9/2014)... critically ill children with traumatic injuries have identified ... likely to develop a hospital-acquired infection. The study, ... published online in June in the journal ... that could lead to the clinical implementation of ... or reverse immune system damage following critical illness ...
    (Date:7/9/2014)... 100 diseases that can attack soybean crops, why would ... wanted list? University of Illinois scientists cite the earth,s ... needed on the fungus that causes charcoal rot. , ... conditions but Macrophomina phaseolina , the fungus that ... , "As the climate continues to change and we ...
    Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
    ... EUREKA Chairmanship 2009/2010! The conference, hosted and conceptually designed ... be held on July 6-7, 2009, at Maritim Hotel ... heart of the city, only a few steps away ... the current and future opportunities and challenges for Europe,s ...
    ... used by millions worldwide to effectively lower blood cholesterol ... Sclerosis (MS) patients treated with high daily dosages. ... Institute (MNI), McGill University, demonstrates that statin therapy in ... nervous system. The findings, published in The American ...
    ... to model in mice because their symptoms are complex ... when transferred to a mouse. The lack of animal ... By strategically altering a protein-making molecule, a mouse was ... feeling and cause paralysis of the arms and legs ...
    Cached Biology News:One size does not fit all 2A new mouse model provides insight into genetic neurological disorders 2
    Request Info...
    2 ml SmartScan Racks...
    ... Immunogen: Partially purified ... MA1-710 detects vitamin D receptor (VDR) ... amphibian, and fish tissues. This ... or glucocorticoid receptors. MA1-710 detects ...
    ... The integration of 2D polyacrylamide gel electrophoresis ... regarded as a core technology platform for ... power for complex samples limited only in ... small and large proteins. Quantitative image based ...
    Biology Products: